Emergent BioSolutions | EBS - Процентные расходы





Процентные расходы Изменить Дата
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Akebia Therapeutics 362.52M 357.69M 2026-03
ALKERMES USD 20.89M 8.62M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amarin USD 3K 5K 2024-12
ANI Pharmaceuticals USD 4.41M 316K 2025-12
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Coherus Biosciences USD 2.25M 76K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Glaxosmithkline GBP 192.73M 14.79M 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
Lonza CHF 84M 14M 2025-06
Merck USD 479M 67M 2026-03
Moderna USD 11.49B 36B 2026-03
Myriad Genetics USD 4.4M 600K 2025-12
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Pacira USD 3.7M 193K 2026-03
Pfizer USD 671M 40M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Sanofi EUR 178M 203M 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Xoma USD 3.4M 150K 2024-06